A simple method to estimate antimalarial drug-related fall in hematocrit (FIH) after treatment of Plasmodium falciparum infections in the field is described. The method involves numeric estimation of the relative difference in hematocrit at baseline (pretreatment) and the first 1 or 2 days after treatment begun as numerator and the corresponding relative difference in parasitemia as the denominator, and expressing it per 1000 parasites cleared from peripheral blood. Using the method showed that FIH/1000 parasites cleared from peripheral blood (cpb) at 24 or 48 hours were similar in artemetherlumefantrine and artesunate-amodiaquine-treated children (0.09; 95% confidence interval, 0.052-0.138 vs 0.10; 95% confidence interval, 0.069-0.139%; P = 0.75) FIH/1000 parasites cpb in patients with higher parasitemias were significantly (P , 0.0001) and five-to 10-fold lower than in patients with lower parasitemias suggesting conservation of hematocrit or red cells in patients with higher parasitemias treated with artesunate-amodiaquine or artemether-lumefantrine. FIH/1000 parasites cpb were similar in anemic and nonanemic children. Estimation of FIH/1000 parasites cpb is simple, allows estimation of relatively conserved hematocrit during treatment, and can be used in both observational studies and clinical trials involving antimalarial drugs.
INTRODUCTION
Anemia, a complication of untreated Plasmodium falciparum malaria in infected individuals living in areas of high and low intensities of transmission, 1-4 is attributable to destruction of parasitized and nonparasitized erythrocytes and variable degree of dyserythropoiesis. 2, [5] [6] [7] Estimation of the extent of red blood cell destruction, red blood cell loss, and of the survival times of both parasitized and nonparasitized red cells [5] [6] [7] [8] during falciparum infections requires detection of red blood cells with ring-infected erythrocyte surface antigen (Pf 155) and use of 51 Cr -labeled red cells, 7, 9 techniques not readily available in much of sub-Saharan Africa where the burden of malaria is greatest. Alternative, simple methods for estimating red cell loss or destruction for field use are urgently needed in endemic areas. A simple method for estimating the effects of antimalarial drugs on hematocrit that uses the difference in baseline hematocrit and parasite density levels and those of the same values a day or 2 after treatment began; fall in hematocrit per 1000 parasites cleared from peripheral blood after treatment with antimalarial drugs is described.
MATERIALS AND METHODS

Patients
The study patients were enrolled at the malaria clinic of the University College Hospital, Ibadan, Nigeria, between July 2009 and August 2010. Inclusion criteria were: informed written consent, age 0.5 to 15 years, single-species asexual P. falciparum parasitemia 2000/mL or greater, no history of antimalarial drug intake in the 2 weeks preceding presentation, and a good likelihood of being able to complete 6 weeks of follow-up. Patients with severe malaria, 10 severe malnutrition, serious underlying diseases (renal, cardiac, or hepatic), and known allergy to study drugs were excluded from the study. The study protocol was approved by the Ethics Committee of the Ministry of Health, Ibadan, Nigeria.
After clinical assessment, blood was obtained for hematocrit determination and for quantification of asexual and sexual parasitemia. Patients were randomized to receive at a ratio of 2:3 standard doses of artemether-lumefantrine (AL) or artesunate plus amodiaquine (AA) as previously described. 11
Laboratory Investigations
Asexual parasite and gametocyte counts and hematocrit (from capillary blood) were measured pretreatment (0 hour, Day 0) and then at 1, 2, 4, 8, 16, and 24 hours and daily on Days 2 to 7, and thereafter on Days 14, 21, 28, 35, and 42. Quantification in Giemsa-stained thick blood films was done against 500 leukocytes and assuming a leukocyte count of 6000/mL of blood as previously described. 11 Anemia was defined as a hematocrit value less than 30%.
Fall in Hematocrit per 1000 Parasites Cleared From Peripheral Blood
Fall in hematocrit per 1000 parasites cleared from peripheral blood (FIH/1000 parasites cpb) was calculated as the difference in hematocrit values at baseline (pretreatment, Day 0) and the first 1 (Day 1) or 2 (Day 2) days after treatment began as the numerator and the difference in baseline (pretreatment) parasitemia and the parasitemia on the first 1 or 2 days after treatment began as the denominator and expressing it per 1000 parasites cleared from peripheral blood. The unit of quantification is percent if hematocrit values were used or grams per deciliter if hemoglobin values were used. Hematocrit conservation ratio was defined as the ratio of fall in hematocrit per1000 parasites cleared from peripheral blood at a particular level of parasitemia and below divided by the corresponding value of fall in hematocrit for parasitemias above this level. Conventional drug-attributable fall in hematocrit was defined American Journal of Therapeutics (2014) 21 (3) www.americantherapeutics.com as the difference between the patient's hematocrit values on Day 0 and Day 3 after treatment.
Data Analysis
Data were analyzed using Version 6 of the Epi-Info software, 12 and the statistical program SPSS for Windows Version 10.01. 13 Variables considered in the analysis were related to the densities of P. falciparum gametocytes and trophozoites. Proportions were compared by calculating chi square with Yates correction or by Fisher exact or by Mantel Haenszel tests. Association between FIH determined by FIH/1000 parasites cpb and the difference between hematocrit values at baseline and 3 days after treatment began was assessed by Pearson correlation coefficient. P values of # 0.05 were taken to indicate significant differences.
RESULTS
Three hundred sixty children were evaluated. Anemia was present in 105 children. The characteristics of the children enrolled and their therapeutic responses are shown in Table 1 . Fever and parasite clearance were significantly shorter in AA-than in AL-treated children ( Table 1) . There was no fall in hematocrit between Day 0 and Day 3 in 200 children. There were decreases of varying degrees in 160 children. Except for a significantly higher body temperature (38.5 6 1.0 vs 38.3 6 1.0 o C, P = 0.04), the characteristics, at presentation, of the children with or without fall in hematocrit after treatment were similar.
Mean and the distribution of individual values of fall in hematocrit per 1000 parasites cleared from peripheral blood (FIH/1000 parasites cpb) were similar in AL-and AA-treated children (0.09; 95% confidence interval [CI], 0.052-0.138; range, 0.01-0.83 vs 0.10; 95% CI, 0.069-0.139; range, 0.01-1.22%; P = 0.75; Fig. 1 ).
At all levels of parasitemia from 200,000/mL blood, FIH/1000 parasites cpb values were significantly higher in those with low compared with those with high parasitemias ( Table 2 ). In children with parasitemias of greater than 200,000/mL, the relative change was 10-fold higher. Using the difference between hematocrit on Days 0 and 3, FIH values were similar in patients with high and low parasitemia except at parasitemia levels of 150,000/mL and 175,000/mL blood ( Table 3 ). The relative change in FIH value was less than 1 at all levels of parasitemia.
Comparison of hematocrit conservation ratio by the two methods showed that values of the ratio at all levels of parasitemia were significantly higher using FIH/1000 parasites cpb than the values using the differences between pretreatment and Day 3 hematocrit value (P , 0.000001 for all levels of parasitemia; see the ratio columns of Tables 2 and 3 ). There was a significantly positive correlation between the fall in hematocrit calculated by the two methods after treatment with AL or AA (r = 0.24, P = 0.027).
Values of FIH/1000 parasites cpb for a broad range of parasitemias were similar in children with or without anemia. For example, at a parasitemia level of greater than 250,000/mL, the respective values were 0.009 6 0.003 (standard error of mean) (n = 4) and 0.016 6 0.004 (n = 9) (P = 0.32) in anemic and nonanemic children. At a parasitemia level of 50,000/mL or less, the corresponding values were 0.17 6 0.04 (n = 18) and 0.20 + 0.03 (n = 49) (P = 0.59) in anemic and nonanemic children. 
DISCUSSION
In the present study, relating the fall in hematocrit to 1000 parasites cleared from peripheral blood within a time frame of 24 to 48 hours permitted estimation of falls and the falls at all levels of parasitemia in an objective manner in children treated with rapidly acting schizontocidal antimalarials. Falls in hematocrit at high levels of parasitemia were much lower than at low levels of parasitemia suggesting much conservation of hematocrit or red blood cells in patients with hyperparasitemia treated with artemisinin-based combination drugs. This finding supports, in a qualified manner, that from more sophisticated studies that quantified ring-infected erythrocyte surface antigenpositive parasite-negative red blood cells and showing that rapid malaria clearance after treatment with artemisinin derivatives results from the extraction of drug-affected parasites from host erythrocytes, presumably by the spleen. 9 Thus, the relatively high hematocrit conservation ratio observed in the present study may partly explain why the fall in hematocrit after treatment of hyperparasitemia is often less than that predicted from loss of parasitized red blood cell in patients treated with artemisinin-based combination drugs.
Although there was no fall in hematocrit in over half of the patients, it was difficult clinically to distinguish patients with or without a fall. Falls in hematocrit in anemic children were not worsened by administration of AL and AA. One fourth or one fifth of African children and adolescents may be glucose-6-phosphate dehydrogenase-deficient. 14 In these children, the anemia of malaria may be further worsened by some antimalarial drugs. 14 It has been estimated that for every parasitized red blood cell destroyed, 10 uninfected red cells are destroyed. 6 The method described cannot distinguish between infected and noninfected red cells removed from the circulation during infection, but it allows quantification of change in hematocrit relative to the number of parasites cleared from peripheral blood after treatment of infections, a practical advantage in the field and one requiring no skill greater than for the quantification of parasitemia by microscopy counts. The method can be used in drug studies involving different regimens. American Journal of Therapeutics (2014) 21 (3) www.americantherapeutics.com Table 3 . Comparison of fall in hematocrit based on the difference between pretreatment and 3 days after treatment began in patients with varying degrees of parasitemia who were treated with artemether-lumefantrine or artesunateamodiaquine.
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